Making Cancer Care More Equitable with Diagnostics


Genomic Ancestry Research

We partner with researchers across the globe to conduct retrospective studies leveraging our unique cancer dataset to understand if there are biological differences by ancestry that can help to design more personalized approaches to care in the future. Our large and diverse datasets help guide patients and physicians to more accurate diagnostics and targeted clinical trials across all genomic ancestral populations. See our recent research

Awareness, Access & Education Initiatives

We remain deeply committed to addressing education, awareness and access challenges in testing through Foundation Medicine-driven programs and services, such as our FoundationAccessTM program, our work with Medicaid programs and patient-specific resources and services and through our giving initiatives and coalition involvement. We are dedicated to providing genomic testing and personalized oncology solutions to all patients, regardless of their socioeconomic status. In line with this commitment, we are working to expand access to our testing for Medicaid-insured populations.

By working with Medicaid programs across the country, we are helping to enable more patients to obtain access to personalized cancer treatment plans based on their unique genetic profiles. Medicaid coverage of our tests continues to grow, making it easier for patients with limited resources to benefit from the latest advances in precision medicine. This builds on the broad national and regional coverage for our FoundationOne®CDx and FoundationOne®Liquid CDx tests, including Medicare, Medicare Advantage, and the Veterans Administration (VA).


Call for Grants Notification

Foundation Medicine issued a formal Call for Grants Notification (CGN) in Q4 2022. The CGN sought projects/initiatives aimed at increasing biomarker testing education, awareness, and access among underserved populations in the U.S. LUNGevity Foundation and Moffitt Cancer Center were selected to receive the grant and will be using the funds to develop patient-friendly educational materials that provide accurate and balanced information about personalized healthcare and genomic testing.

Research organized by disease area 


Genomic Ancestry in B-Cell Lymphoid Malignancies.


Comparison of PIK3CA mutation prevalence in breast cancer across predicted ancestry populations.

The impact of coding germline variants on contralateral breast cancer risk and survival.


Comprehensive genomic profiling (CGP) defines the genomic landscape of colorectal cancer (CRC) in individuals of African ancestry.

The Genomics of Colorectal Cancer in Populations with African and European Ancestry.


Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns.

Comprehensive genomic profiling (CGP) of gall bladder adenocarcinoma (GBAC) in patients from distinct ancestral populations.

Landscape of BRAF mutation classes in intrahepatic cholangiocarcinoma.

Molecular profiling of biliary tract cancers in patients of African and European ancestries.


Age-, sex-, and race-related differences in outcomes of patients with muscle-invasive bladder cancer treated with radical cystectomy: The role of biology versus access to standard medical care.

Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry.

Comparative genomic alterations (GA) landscape in urothelial carcinoma of the bladder (UCB) in patients of South Asian ancestry (SAS).


Advanced cancers amongst individuals of African ancestry exhibit an almost five-fold higher prevalence of high-risk HPV types not covered by the current 9-valent vaccine.

Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma.

Comprehensive genomic profiling (CGP) of uterine carcinosarcomas (UCS) reveals unique ancestry features and both molecular similarities and differences when compared to endometrial serous carcinomas.

Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.


Ancestry-based differences in gene alterations in non–small cell lung cancer: Real-world data using genetic ancestry analysis.

Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation.


Ancestral characterization of the genomic landscape, comprehensive genomic profiling utilization, and treatment patterns may inform disparities in advanced prostate cancer: A large-scale analysis.

Genomic Profiling of Prostate Cancers from Men with African and European Ancestry.


Prevalence of High-Risk Nonvaccine Human Papillomavirus Types in Advanced Squamous Cell Carcinoma Among Individuals of African vs Non-African Ancestry.


Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients.

Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer.

Determining patient ancestry based on targeted tumor comprehensive genomic profiling.

Disparities According to Genetic Ancestry in the Use of Precision Oncology Assays.

Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumours from >165,000 pan-solid tumours.

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.

Leveraging existing data to identify ancestry-associated features across multiple cancer types.

Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.

Not all TMB assays are the same: Clinical validity of robust algorithmic germline filtering.

Pan-cancer analysis of sex differences and their associations with ancestry and genomic biomarkers in a large comprehensive genomic profiling dataset.

Somatic genome alterations in cancer as compared to inferred patient ancestry.

Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.


Join Us

We know what’s next because, at Foundation Medicine, we’re the ones 
creating it.

View Careers